GLSI Greenwich LifeSciences, Inc.

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.

$31.77  -0.06 (-0.19%)
As of 11/30/2021 15:58:30 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  09/25/2020
Outstanding shares:  13,018,061
Average volume:  20,445
Market cap:   $430,897,819
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    396879108
ISIN:        US3968791083
Sedol:      BLF0C50
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   14.53
PS ratio:   0.00
Return on equity:   -14.31%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy